Skip to main content
I

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2026-03-10 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a short announcement (1359 characters) from Immunotech Biopharm Ltd stating that a board meeting will be held on 20 March 2026 to consider and approve the annual results for the year ended 31 December 2025. This is a standard 'Notice of Board Meeting' which serves as an announcement regarding the upcoming publication of a report, fitting the definition of a Report Publication Announcement (RPA).
2026-03-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory filing used by listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' but is a mandatory regulatory disclosure required by the Exchange Listing Rules. Therefore, it is classified as a Regulatory Filing (RNS).
2026-03-03 English
DISCLOSEABLE TRANSACTION SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCT
Regulatory Filings Classification · 1% confidence The document is an official announcement from Immunotech Biopharm Ltd regarding a 'Discloseable Transaction' involving the subscription of a structured deposit product. It explicitly references the Listing Rules of the Stock Exchange of Hong Kong (Chapter 14) regarding disclosure requirements for transactions exceeding certain percentage ratios. Since this is a specific corporate announcement regarding a financial transaction that does not fit into categories like M&A (TAR) or capital raising (CAP), and is not a periodic report, it falls under the general regulatory announcement category.
2026-02-25 English
COMPLETION OF ISSUE OF NEW CONVERTIBLE BONDS UNDER GENERAL MANDATE AND THE NOTE AND SETTLEMENT OF THE 2023 CONVERTIBLE BONDS
Capital/Financing Update Classification · 1% confidence The document is an official announcement from Immunotech Biopharm Ltd regarding the completion of the issuance of new convertible bonds and the settlement of existing 2023 convertible bonds. It details the financial transaction, the impact on the company's shareholding structure, and confirms the fulfillment of conditions precedent. This falls under the category of capital and financing updates, as it relates to the company's capital structure and debt instruments.
2026-02-13 English
PROPOSED ISSUE OF NEW CONVERTIBLE BONDS UNDER GENERAL MANDATE AND THE NOTE AND SETTLEMENT OF THE 2023 CONVERTIBLE BONDS
Capital/Financing Update Classification · 1% confidence The document is an official announcement from Immunotech Biopharm Ltd regarding the proposed issuance of new convertible bonds and a note to settle existing 2023 convertible bonds. It details the subscription agreement, conversion price, terms of the bonds, and security arrangements. This falls under the category of capital structure changes and financing activities.
2026-02-09 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2026
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. Since it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which usually refers to a specific event) or 'Director's Dealing', it is best classified as a Regulatory Filing (RNS).
2026-02-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.